FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

- D C 20E40	
n, D.C. 20549	│ OMB APPRO
	OND AFFIXO

VAL OMB Number: 3235-0287 Estimated average burden hours per response 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					OI	i Seci	1011 30(11)	oi tile	investmen	COI	ipany Act	01 1940								
Name and Address of Reporting Person* Scibetta James S				2. Issuer Name and Ticker or Trading Symbol Aquestive Therapeutics, Inc. [AQST]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
SCIDELL	<u>a Jaines S</u>	<u>l</u>				•			,			-		X Di	ector			10% Ov	/ner	
(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year) 06/16/2020									icer (er (give title v)		Other (s below)	pecify	
C/O AQ	UESTIVE T	THERAPEUTIC	S, INC.																	
30 TECHNOLOGY DRIVE					4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)													"	,	rm file	ed by One	Reno	rting Persor	1	
WARRE	N N	J	07059											Fo		,		One Repor		
(City)	(S	tate)	(Zip)																	
		Tal	ole I - Nor	n-Deriv	vativ	e Se	curitie	s Ac	quired,	Dis	osed o	f, or Ber	neficia	lly Ow	ned					
1. Title of Security (Instr. 3) 2. Trans: Date (Month/I						2A. Deemed Execution Date, if any (Month/Day/Yea		, Transaction Disposed Code (Instr. 5)			ties Acquired (A) or I Of (D) (Instr. 3, 4 a		l and Securitie Beneficia Owned F		es For ally (D) following (I) (m: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) or (D)	Price	Trai		d tion(s) and 4)			(Instr. 4)	
Common Stock															31,635			D		
			Table II -									or Bene ole secu		y Owne	d					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Deriva Secur	tive ty	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable		Expiration Date	Title	Amoun or Numbe of Shares	r						
Stock Option (Right to Purchase)	\$5.3	06/16/2020			A		14,000		06/16/2021	(1)	06/16/2030	Common Stock	14,00	30		14,000	0	D		

Explanation of Responses:

1. The shares underlying the options vest as follows: 100% of the underlying shares vest June 16, 2021, subject to Mr. Scibetta's continuous service with the Issuer from the grant date through the applicable vesting date.

Remarks:

/s/ Robert Arnold, as Attorney-

06/18/2020

In-Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.